Progressive Supranuclear Palsy (PSP): Clinical Trials

2 trials for Progressive Supranuclear Palsy (PSP), newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 32Completed 2

Follow Progressive Supranuclear Palsy (PSP): new trials by email Literature Review of Progressive Supranuclear Palsy (PSP) trials Research Report on Progressive Supranuclear Palsy (PSP)

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
DaTSCAN™ Ioflupane (123I) Injection - Parkinsonian Syndrome, Parkinson Disease(PD)
Phase 3CompletedGE Healthcare1722020-06-282023-10-16
Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy
Rivastigmine, Placebo - Progressive Supranuclear Palsy (PSP)
Phase 3CompletedAssistance Publique Hopitaux De Marseille1062016-07-262023-07-20

Narrower conditions

Supranuclear Palsy, Progressive (2)  ·  Essential Tremor (1)  ·  Multiple System Atrophy (1)  ·  Parkinson Disease (1)  ·  Parkinsonian Disorders (1)

Broader conditions

Basal Ganglia Diseases (2)  ·  Brain Diseases (2)  ·  Central Nervous System Diseases (2)  ·  Cranial Nerve Diseases (2)  ·  Eye Diseases (2)  ·  Movement Disorders (2)  ·  Nervous System Diseases (2)  ·  Neurodegenerative Diseases (2)  ·  Neurologic Manifestations (2)  ·  Ocular Motility Disorders (2)  ·  Ophthalmoplegia (2)  ·  Paralysis (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Signs and Symptoms (2)  ·  Tauopathies (2)

Interventions

Injections (1)  ·  Iodine-123 (1)  ·  Rivastigmine (1)  ·  ioflupane (1)

Sponsors

Assistance Publique Hopitaux De Marseille (1)  ·  GE Healthcare (1)

Countries

China (1)  ·  France (1)

NIH funding

2016 (1)